Marinus Pharmaceuticals Inc (STU:61Y)
€ 0.292 0.076 (35.19%) Market Cap: 19.67 Mil Enterprise Value: 32.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 36/100

Marinus Pharmaceuticals, Inc. - Special Call Transcript

Jul 23, 2019 / 12:00PM GMT
Release Date Price: €4.57 (-66.47%)
Operator

Greetings. Welcome to Marinus PPD data webcast. (Operator Instructions).

Please note this conference is being recorded. I would now like to turn the conference over to Lisa Caperelli with IR. Thank you. You may begin.

Lisa M. Caperelli
Marinus Pharmaceuticals, Inc. - Executive Director of Investor & Strategic Relations

Thank you, Sherry. Good morning, everyone, and thank you for joining this conference call where we will review data from our Magnolia and Amaryllis Phase II clinical studies, evaluating ganaxolone treatment regimens in women with Postpartum Depression.

Participants on today's call are Dr. Scott Braunstein, Executive Chairman of Marinus; and Dr. Lorianne Masuoka, our Chief Medical Officer. Dr. Kimberly McCormick, our Head of Regulatory Affairs; and Edward Smith, our CFO, are also on the line and will be available to answer questions during the Q&A session.

There are slides accompanying today's call in order to access these slides, please log into the webcast that's accessible from the Investor Relations

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot